Últimas noticias sobre Quest Diagnostics (NYSE:DGX) Bolsa

QUEST DIAGNOSTICS INC

Quest Diagnostics

Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

News

Quest Diagnostics Launches Diagnostic Laboratory Test For Emerging Infectious Disease Associated With Severe Neurological Affects

Test to be available for clinical and research use as soon as this summer, building on Quest's pioneering blood-based AD-Detect&#x2122; product line for assessing symptomatic patients
SECAUCUS, N.J., July 9, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4464498-1&amp;h=2423927372&amp;u=https%3A%2F%2Fwww.fujirebio.com%2Fen-us%2Fnews-events%2Ffujirebio-receives-marketing-clearance-for-lumipulser-g-ptau-217bamyloid-142-plasma-0&amp;a=Lumipulse%C2%AE+G+pTau+217%2F%CE%B2-Amyloid+1-42+Plasma+Ratio">Lumipulse&#xAE; G pTau 217/β-Amyloid 1-42 Plasma Ratio</a>&nbsp;in-vitro diagnostic (IVD) test from Fujirebio, a global leader in the field of high-quality IVD testing.
Quest plans to make the test available to physicians and biopharmaceutical collaborators later this summer. The test is the first blood-based IVD test cleared by the U.S. Food and Drug Administration (FDA) to aid in identifying patients with amyloid pathology associated with Alzheimer's disease. It is designed to aid the clinical assessment of Alzheimer's disease in adult patients aged 50 years and older presenting at a specialized care setting with signs and symptoms of cognitive decline.
Through its AD-Detect&#x2122; portfolio, Quest provides a suite of advanced lab-developed blood tests regulated under CLIA for assessing patients with cognitive impairment for Alzheimer's disease. The Fujirebio test offering extends this portfolio to include an FDA-cleared option for use in specialized care settings.
Quest will showcase its complete line up of Alzheimer's and other neurological test innovations at this year's Alzheimer's Association International Conference (AAIC) in Toronto from July 27-31.

Quest Diagnostics Plans To Offer Laboratory Testing Based On Lumipulse G pTau 217/Β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test From Fujirebio

Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) has outperformed the market over the past 5 years by 304.48% on an annualized basis producing an average annual return of 318.82%. Currently, Quest Diagnostics has a market capitalization of $19.42 billion. 
Buying $1000 In DGX: If an investor had bought $1000 of DGX stock 5 years ago, it would be worth $1,448,542.88 today based on a price of $173.97 for DGX at the time of writing.
<h3>Quest Diagnostics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751920211_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Personalized medicine, which involves tailoring treatment to a patient&#8217;s unique disease profile, is widely regarded as the holy grail of medicine. However, the current implementation of this approach faces significant hurdles.
Bank of America Securities (BofA) highlights that the precision medicine approach is currently <a target="_blank" href="https://www.benzinga.com/topic/artificial-intelligence" rel="noreferrer noopener">cost, labor, and time-intensive</a>.
Analysts Alec Stranahan and Michael Ryskin specifically point out that the substantial amount of manual work involved in processing complex biological data and making treatment decisions leads to considerable delays.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/06/45820489/goldman-sachs-bullish-on-branded-drug-upside-at-teva-what-about-viatris" rel="noreferrer noopener">Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?</a>
Beyond the practical challenges, precision medicine also grapples with data validation issues. Given the infinitely complex nature of biology and the huge number of interactions between biological systems, researchers often run into issues with validating the impact of genes/pathways associated with disease progression/response to treatment.
Despite these inherent challenges, the integration of Artificial Intelligence (AI) and Machine Learning (ML) is widely recognized as a pivotal enabler for advancing precision medicine.
Consequently, a number of companies are actively leveraging these technologies to innovate within the precision medicine landscape, striving to make tailored treatments more accessible, efficient, and effective.
These companies include Tempus AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), Guardant Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>), Exact Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), NeoGenomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>), Quest Diagnostics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>), and LabCorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), each employing AI in unique ways to enhance diagnostics, therapy selection, and overall patient care across the care continuum.
<h2 class="wp-block-heading">Tempus AI</h2>
BofA analyst says Tempus AI perfectly fits the theme of <a target="_blank" href="https://www.benzinga.com/news/movers-shakers/25/06/45726456/tempus-ai-stock-is-surging-today-what-investors-are-watching" rel="noreferrer noopener">AI in precision medicine</a>.
Like most MDx companies, Tempus AI has built its business off an industry-leading database of clinico-genomic data. Tempus leverages this data by training AI/ML algorithms to parse through the data and detect patterns and anomalies.&nbsp;&nbsp;
BofA reiterates a Neutral rating for Tempus AI, given its already premium valuation. The analyst remains constructive on the business and key markets. However, due to peer group expansion, BofA raised its price <a target="_blank" href="https://www.benzinga.com/quote/TEM/analyst-ratings" rel="noreferrer noopener">forecast from $68 to $70</a>.
<h2 class="wp-block-heading">Guardant Health</h2>
Guardant Health was an early mover in the liquid biopsy cancer testing/therapy selection market with their <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/45756387/why-is-cancer-diagnostic-guardant-health-stock-trading-higher-on-tuesday" rel="noreferrer noopener">Guardant 360 (G360) test</a>.
Guardant Health has a clear goal to build upon its G360 test (therapy selection) and expand across the care continuum, thus allowing it to participate in a patient&#8217;s receiving precision medicine at all stages post-cancer diagnosis.
Guardant Health has its business built on the algorithms that it runs.
BofA <a target="_blank" href="https://www.benzinga.com/quote/GH/analyst-ratings" rel="noreferrer noopener">maintains a Buy rating</a> on Guardant Health, given its leading position, strong growth profile, and upcoming catalyst path for new products.
<h2 class="wp-block-heading">Exact Sciences</h2>
BofA analysts say Exact Sciences Corp. has expanded to offer services <a href="https://www.benzinga.com/general/health-care/25/05/45165534/cancer-diagnostic-firm-exact-sciences-ceo-says-strong-q1-paves-way-for-transformative-2025-lifts-annual-guidance" target="_blank" rel="noreferrer noopener">across the care continuum</a>.
While Exact Sciences started screening for colorectal cancer specifically, their focus has been steered towards all indications and across the treatment paradigm.
Exact Sciences&#8217; legacy Cologuard test / early detection doesn&#8217;t necessarily &#8220;fit&#8221; the precision medicine theme; however, everything Exact has done since is &#8220;precision medicine / AI-aligned,&#8221; BofA added in its investor note on Wednesday.
Given its strong financial profile and near-term catalyst path, the analyst maintains a <a target="_blank" href="https://www.benzinga.com/quote/EXAS/analyst-ratings" rel="noreferrer noopener">Buy rating on Exact Sciences</a>.
<h2 class="wp-block-heading">NeoGenomics</h2>
NeoGenomics has been known as a traditional reference lab offering many hotspot tests. However, by adding the PanTracer testing family and data services offering, NeoGenomics leverages the numerous hotspot data points and can build those into a more robust AI algorithm to inform the more modern therapy selection tests.
The dataset/algorithm and 500+ tests create a flywheel where the tests that are sold generate information. The information informs the algorithm, eventually leading to more accurate algorithms, which help market the tests… bring you back to more tests.
BofA <a target="_blank" href="https://www.benzinga.com/quote/NEO/analyst-ratings" rel="noreferrer noopener">maintains a Neutral rating</a> on NeoGenomics given near-term headwinds and more limited upside versus its prior trajectory.
<h2 class="wp-block-heading">Quest Diagnostics</h2>
Quest Diagnostics is showing trends toward AI in precision medicine with <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44929366/quest-diagnostics-revenue-rebound-strategic-moves-fuel-outlook-confidence" rel="noreferrer noopener">Haystack and PathAI Quest</a>.
While not traditionally considered a &#8220;leader&#8221; in AI/precision medicine, Quest Diagnostics has shown progress toward becoming a company to watch.
At DGX&#8217;s 2025 Investor Day, management discussed innovations in lab diagnostics, including the adoption of AI and automation. Given Quest Diagnostics&#8217; strong, steady performance and lower exposure to macro/policy overhangs, the analyst <a target="_blank" href="https://www.benzinga.com/quote/DGX/analyst-ratings" rel="noreferrer noopener">maintains a Buy rating</a>.
<h2 class="wp-block-heading">LabCorp</h2>
LabCorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) aims to be a notable player in AI precision medicine. Although LabCorp is known as a traditional reference lab, with trends toward AI and precision medicine, LH has shown signs of <a target="_blank" href="https://www.benzinga.com/25/02/43539754/labcorp-reports-q4-earnings-beat-and-expects-strong-2025-growth-analyst-reiterates-outperform-on-stable-2025-outlook" rel="noreferrer noopener">jumping on the bandwagon</a>.
While LabCorp already offers NGS tests, there appears to be a clear trend and focus towards advancing its AI/precision medicine portfolio.
BofA <a target="_blank" href="https://www.benzinga.com/quote/LH/analyst-ratings" rel="noreferrer noopener">maintains a Buy rating</a> on LabCorp, given strong and steady performance and lower exposure to macro/policy overhangs.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/06/46100456/tesla-robotaxi-scaling-growth-will-be-slow-in-near-term-goldman-sachs" target="_blank" rel="noreferrer noopener">Tesla Robotaxi Scaling Growth Will Be Slow In Near Term: Goldman Sachs</a></li>
</ul>
Photo by Piotr Swat via Shutterstock

Analyst Color

Biotech

Health Care

Analyst Ratings

General

EXAS

Laboratory Corporation Of America Holdings

Could Personalized Medicine Be Your Portfolio's Next Big Winner? Find Out

Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) has outperformed the market over the past 5 years by 299.46% on an annualized basis producing an average annual return of 313.78%. Currently, Quest Diagnostics has a market capitalization of $20.33 billion. 
Buying $100 In DGX: If an investor had bought $100 of DGX stock 5 years ago, it would be worth $109,220.16 today based on a price of $182.07 for DGX at the time of writing.
<h3>Quest Diagnostics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750115712_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Quest Diagnostics Stock In The Last 5 Years

Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>), a leading provider of diagnostic information services, today announced a collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) designed to improve the assessment of elevated risk of cancer in individuals who would benefit from medically appropriate cancer screenings.
Under terms of the agreement, Quest will develop and validate a laboratory-developed blood test based on circulating protein biomarkers associated with high risk for one or more cancers, including colorectal, lung, breast, pancreatic, ovarian, liver, prostate, esophageal and stomach. Quest will base the test on a developmental license to technology and intellectual property associated with the Multi-Cancer Stratification Test (MCaST), a cohesive risk model developed by the laboratory of Samir Hanash, M.D., Ph.D., at MD Anderson. Dr. Hanash and his team identified a set of biomarkers that inform the model through extensive clinical research conducted on screening study cohorts involving tens of thousands of individuals. Quest plans to refine and further develop and validate the MCaST technology for its own lab-developed test.
&nbsp;

Quest Diagnostics Collaborates With MD Anderson To Develop Multi-Cancer Stratification Blood Test

Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) has outperformed the market over the past 5 years by 276.89% on an annualized basis producing an average annual return of 290.74%. Currently, Quest Diagnostics has a market capitalization of $19.32 billion. 
Buying $1000 In DGX: If an investor had bought $1000 of DGX stock 5 years ago, it would be worth $1,019,647.06 today based on a price of $173.07 for DGX at the time of writing.
<h3>Quest Diagnostics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748637015_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) has outperformed the market over the past 5 years by 305.46% on an annualized basis producing an average annual return of 320.73%. Currently, Quest Diagnostics has a market capitalization of $19.47 billion. 
Buying $1000 In DGX: If an investor had bought $1000 of DGX stock 5 years ago, it would be worth $1,318,296.30 today based on a price of $174.39 for DGX at the time of writing.
<h3>Quest Diagnostics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747437313_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Needham cut ON Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) price target from $57 to $50. Needham analyst Quinn Bolton maintained a Buy rating. ON Semiconductor shares closed at $38.41 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/ON/analyst-ratings">view this stock</a>.</li>
<li>Compass Point slashed the price target for MARA Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) from $25 to $9.5. Compass Point analyst Joe Flynn downgraded the stock from Neutral to Sell. MARA Holdings shares closed at $13.09 on Monday. <a href="https://www.benzinga.com/quote/MARA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Leerink Partners cut Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) price target from $550 to $503. Leerink Partners analyst David Risinger downgraded the stock from Outperform to Market Perform. Vertex Pharmaceuticals shares closed at $500.19 on Monday. See how other analysts view <a href="https://www.benzinga.com/quote/VRTX/analyst-ratings">this stock</a>.</li>
<li>HC Wainwright &amp; Co. raised the price target for Solaris Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLSR#NYSE">SLSR</a>) from $10 to $11. HC Wainwright &amp; Co. analyst Heiko Ihle maintained a Buy rating. Solaris Resources shares closed at $4.33 on Monday. <a href="https://www.benzinga.com/quote/SLSR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group slashed the price target for Ethan Allen Interiors Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETD#NYSE">ETD</a>) from $32 to $30. Telsey Advisory Group analyst Cristina Fernandez maintained a Market Perform rating. Ethan Allen Interiors shares closed at $29.13 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/ETD/analyst-ratings">view this stock</a>.</li>
<li>Rosenblatt raised Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) price target from $230 to $250. Rosenblatt analyst Mike Genovese maintained a Buy rating. Fabrinet shares settled at $220.90 on Monday. <a href="https://www.benzinga.com/quote/FN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group cut NIKE, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) price target from $80 to $70. Telsey Advisory Group analyst Cristina Fernandez maintained a Market Perform rating. Nike shares closed at $57.35 on Monday. <a href="https://www.benzinga.com/quote/NKE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity cut Castle Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSTL#NASDAQ">CSTL</a>) price target from $42 to $37. Canaccord Genuity analyst Kyle Mikson maintained a Buy rating. Castle Biosciences shares closed at $18.75 on Monday.  <a href="https://www.benzinga.com/quote/cstl/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan cut the price target for Twist Bioscience Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) from $40 to $33. JP Morgan analyst Rachel Vatnsdal maintained an Underweight rating. Twist Bioscience shares settled at $35.93 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan raised Quest Diagnostics Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) price target from $180 to $190. JP Morgan analyst Lisa Gill maintained a Neutral rating. Quest Diagnostics shares closed at $177.57 on Monday. <a href="https://www.benzinga.com/quote/DGX/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying NKE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="581" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06080300/image-53-1024x581.png" alt="" class="wp-image-903102" style="width:591px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06080300/image-53-1024x581.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06080300/image-53-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06080300/image-53-768x436.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06080300/image-53.png 1116w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more">Jim Cramer Says Applied Materials Is An &#8216;Excellent&#8217; Company, But Likes This Tech Stock More</a> </li>
</ul>
Photo via Shutterstock

Price Target

Pre-Market Outlook

Markets

CSTL

MARA

SLSR

TWST

VRTX

Nike To $70? Here Are 10 Top Analyst Forecasts For Tuesday

JP Morgan analyst Lisa Gill maintains Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) with a Neutral and raises the price target from $180 to $190.

JP Morgan Maintains Neutral on Quest Diagnostics, Raises Price Target to $190

Piper Sandler analyst David Westenberg maintains Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) with a Neutral and raises the price target from $180 to $200.

Piper Sandler Maintains Neutral on Quest Diagnostics, Raises Price Target to $200

Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) has outperformed the market over the past 5 years by 290.7% on an annualized basis producing an average annual return of 304.55%. Currently, Quest Diagnostics has a market capitalization of $19.69 billion. 
Buying $1000 In DGX: If an investor had bought $1000 of DGX stock 5 years ago, it would be worth $1,149,477.12 today based on a price of $175.87 for DGX at the time of writing.
<h3>Quest Diagnostics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745536510_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Quest Diagnostics Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) posted better-than-expected first-quarter <a href="https://www.benzinga.com/quote/DGX/earnings">earnings on Tuesday</a>.
Quest Diagnostics reported quarterly earnings of $2.21 per share which beat the analyst consensus estimate of $2.15 per share. The company reported quarterly sales of $2.65 billion which beat the analyst consensus estimate of $2.63 billion.
"In the first quarter, we delivered strong revenue growth of approximately 12%, including nearly 2.5% in organic growth, as demand rebounded in March following weather impacts early in the quarter. Our growth was due to contributions from acquisitions and large enterprise accounts, demand for our advanced diagnostics portfolio, and expanded health plan access," said Jim Davis, chairman, CEO and president. "We are reaffirming our revenue and adjusted EPS guidance for the full year 2025."
Quest Diagnostics reaffirmed 2025 guidance for revenue of $10.70 billion—$10.85 billion versus the consensus of $10.78 billion and adjusted EPS of $9.55-$9.80 compared to the consensus of $9.68.
Quest Diagnostics shares fell 0.1% to trade at $172.71 on Wednesday.
These analysts made changes to their price targets on Quest Diagnostics following earnings announcement.
<ul>
<li>Baird analyst Eric Coldwell maintained Quest Diagnostics with an Outperform rating and raised the price target from $191 to $194.</li>
<li>Evercore ISI Group analyst Elizabeth Anderson maintained the stock with an In-Line rating and raised the price target from $175 to $180.</li>
<li>Barclays analyst Stephanie Davis maintained Quest Diagnostics with an Equal-Weight rating and increased the price target from $175 to $185.</li>
<li>Truist Securities analyst David Macdonald maintained the stock with a Hold rating and raised the price target from $182 to $190.</li>
</ul>
Considering buying DGX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="591" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23131602/image-139-1024x591.png" alt="" class="wp-image-884833" style="width:582px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23131602/image-139-1024x591.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23131602/image-139-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23131602/image-139-768x443.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23131602/image-139.png 1092w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44950904/tesla-to-303-here-are-10-top-analyst-forecasts-for-wednesday">Tesla To $303? Here Are 10 Top Analyst Forecasts For Wednesday</a> </li>
</ul>
Photo via Shutterstock

Earnings

These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Q1 Earnings

Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) with a Hold and raises the price target from $182 to $190.

Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $190

Barclays analyst Stephanie Davis maintains Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) with a Equal-Weight and raises the price target from $175 to $185.

Barclays Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $185

During the last three months, 12 analysts shared their evaluations of Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $183.25, with a high estimate of $195.00 and a low estimate of $170.00. Observing a 3.91% increase, the current average has risen from the previous average price target of $176.36. 
<img src="https://www.benzinga.com/files/images/story/2025/1745413266_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Quest Diagnostics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Elizabeth Anderson &#x7C;Evercore ISI Group &#x7C;Raises &#x7C;In-Line &#x7C; $180.00&#x7C;$175.00 &#x7C; 
&#x7C;Eric Coldwell &#x7C;Baird &#x7C;Raises &#x7C;Outperform &#x7C; $194.00&#x7C;$191.00 &#x7C; 
&#x7C;Ann Hynes &#x7C;Mizuho &#x7C;Raises &#x7C;Outperform &#x7C; $189.00&#x7C;$178.00 &#x7C; 
&#x7C;Jamie Clark &#x7C;Redburn Atlantic &#x7C;Announces &#x7C;Buy &#x7C; $195.00&#x7C;- &#x7C; 
&#x7C;Eric Coldwell &#x7C;Baird &#x7C;Raises &#x7C;Outperform &#x7C; $191.00&#x7C;$190.00 &#x7C; 
&#x7C;Patrick Donnelly &#x7C;Citigroup &#x7C;Maintains &#x7C;Neutral &#x7C; $185.00&#x7C;$185.00 &#x7C; 
&#x7C;Lisa Gill &#x7C;JP Morgan &#x7C;Raises &#x7C;Neutral &#x7C; $180.00&#x7C;$173.00 &#x7C; 
&#x7C;Ann Hynes &#x7C;Mizuho &#x7C;Raises &#x7C;Outperform &#x7C; $178.00&#x7C;$177.00 &#x7C; 
&#x7C;Kevin Caliendo &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $170.00&#x7C;$166.00 &#x7C; 
&#x7C;David Westenberg &#x7C;Piper Sandler &#x7C;Raises &#x7C;Neutral &#x7C; $180.00&#x7C;$165.00 &#x7C; 
&#x7C;David Macdonald &#x7C;Truist Securities &#x7C;Raises &#x7C;Hold &#x7C; $182.00&#x7C;$172.00 &#x7C; 
&#x7C;Stephanie Davis &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $175.00&#x7C;$168.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Quest Diagnostics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Quest Diagnostics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Quest Diagnostics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into Quest Diagnostics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DGX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Quest Diagnostics analyst ratings.</a>
<h2>Get to Know Quest Diagnostics Better</h2>
Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
<h3>Financial Milestones: Quest Diagnostics's Journey</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Positive Revenue Trend: Examining Quest Diagnostics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 14.55% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Quest Diagnostics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 8.39%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Quest Diagnostics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 3.24%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Quest Diagnostics's ROA excels beyond industry benchmarks, reaching 1.36%. This signifies efficient management of assets and strong financial health.
Debt Management: Quest Diagnostics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.05.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Quest Diagnostics Through 12 Analysts

Evercore ISI Group analyst Elizabeth Anderson maintains Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) with a In-Line and raises the price target from $175 to $180.

Evercore ISI Group Maintains In-Line on Quest Diagnostics, Raises Price Target to $180

Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) with a Outperform and raises the price target from $191 to $194.

Baird Maintains Outperform on Quest Diagnostics, Raises Price Target to $194

Quest Diagnostics Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) reported on Tuesday that first-quarter 2025 sales of $2.65 billion, up 12.1% year over year, beat the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $2.63 billion</a>.
The diagnostic test provider reported quarterly adjusted earnings of $2.21 per share, up 8.3%, <a href="https://www.benzinga.com/pressreleases/25/04/n44917998/quest-diagnostics-reports-first-quarter-2025-financial-results-reaffirms-revenue-and-adjusted-dilu" target="_blank" rel="noreferrer noopener">beating the consensus of $2.15</a>.
&#8220;In the first quarter, we delivered strong revenue growth of approximately 12%, including nearly 2.5% in organic growth, as demand rebounded in March following weather impacts early in the quarter. Our growth was due to contributions from acquisitions and large enterprise accounts, demand for our advanced diagnostics portfolio, and expanded health plan access,&#8221; said Jim Davis, chairman, CEO and president. &#8220;We are reaffirming our revenue and adjusted EPS guidance for the full year 2025.&#8221; 
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/04/44921124/ge-aerospace-expands-q1-operating-margins-ceo-talks-cost-control-to-mitigate-tariff-impact" rel="noreferrer noopener">GE Aerospace Expands Q1 Operating Margins, CEO Talks Cost Control To Mitigate Tariff Impact</a>
Revenue per requisition increased by 0.3%, requisition volume increased 12.4% and organic requisition volume fell slightly by 0.9%.
Adjusted Operating income increased 16.3% to $406 million, while margin improved from 14.8% to 15.3%.
Outlook: Quest Diagnostics reaffirms 2025 guidance for <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43346695/quest-diagnostics-delivers-q4-earnings-beat-the-details" rel="noreferrer noopener">revenue of $10.70 billion—$10.85 billion</a> versus the consensus of $10.78 billion and adjusted EPS of $9.55-$9.80 compared to the consensus of $9.68.
In February, Quest agreed to acquire select assets of Fresenius Medical Care AG&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>) wholly owned Spectra Laboratories. Financial terms were not disclosed. The acquisition is expected to close in the second half of 2025. The transition of services is expected to be <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43910114/fresenius-medical-care-announces-divestment-of-select-laboratory-assets-to-quest-diagnostics" rel="noreferrer noopener">complete by early 2026</a>.
In addition, under a separate agreement, Quest will provide comprehensive laboratory services related to end-stage kidney disease and specialized water testing for patients and providers served by dialysis centers operated by Fresenius Medical Care and its wholly owned and joint-venture partners in the U.S.
In February, GRAIL Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>) and Quest Diagnostics announced the initial phase of a program to improve provider access to GRAIL&#8217;s Galleri multi-cancer early detection test.
Providers can now order the Galleri test directly from GRAIL through the Quest Diagnostics connectivity system that enables providers in the U.S. to order and receive reports of laboratory tests electronically through Quest&#8217;s Quanum laboratory portal and more than 900 electronic health record (EHR) systems. More than 500,000 providers used the Quest connectivity <a href="https://www.benzinga.com/pressreleases/25/02/n43657458/grail-and-quest-diagnostics-provide-grails-galleri-multi-cancer-early-detection-mced-test-through-" target="_blank" rel="noreferrer noopener">system last year</a>.
William Blair writes, &#8220;At first glance, these results are in line with what we would expect from Quest — consistent and with little drama.&#8221;
&#8220;We remain comfortable with the 2025 guide, as Quest continues to benefit from prudent utilization assumptions, mix benefits, flattish unit pricing, a more favorable regulatory environment and plenty of acquisition targets,&#8221; analyst Andrew Brackmann noted.
The William Blair analyst added, &#8220;Beyond the favorable industry backdrop, we believe Quest should be well insulated from macroeconomic noise, with the overwhelming majority of revenue coming from the U.S. and what we think will be minimal (likely offset) impact from tariffs.&#8221; The analyst reiterated the Outperform rating.
DGX Price Action: Quest Diagnostics stock is up 7.83% to $174.53 at publication on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44921668/3m-stock-surges-after-q1-beat-as-2025-outlook-flags-tariff-pressure" target="_blank" rel="noreferrer noopener">3M Stock Surges After Q1 Beat As 2025 Outlook Flags Tariff Pressure</a></li>
</ul>
Photo: Shutterstock

Large Cap

Guidance

Reiteration

Movers

GRAL

Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence

U.S. stocks were higher, with the Dow Jones index gaining around 600 points on Tuesday.
Shares of Quest Diagnostics Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) rose sharply during Tuesday's session following <a href="https://www.benzinga.com/quote/DGX/earnings">better-than-expected first-quarter earnings.</a>
Quest Diagnostics reported quarterly earnings of $2.21 per share which beat the analyst consensus estimate of $2.15 per share. The company reported quarterly sales of $2.65 billion which beat the analyst consensus estimate of $2.63 billion.
Quest Diagnostics shares jumped 7.3% to $173.60 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>PureCycle Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) gained 15% to $6.39. PureCycle announced the sale of approximately $30 million in revenue bonds.</li>
<li>Hesai Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) shares jumped 15% to $13.36. Hesai introduced Infinity Eye, which will be available in three tailored versions A, B, and C. Each one caters to different levels of autonomous driving from basic assisted features to full automation.</li>
<li>NovaGold Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NG#NYSE">NG</a>) gained 14.7% to $3.5697 after the company and Paulson Advisers agreed to acquire Barrick&#8217;s 50% stake in Donlin Gold, forming a new partnership to develop the project.</li>
<li>Cipher Mining Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) surged 14.5% to $2.68.</li>
<li>First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) gained 13.7% to $139.15 after the US finalized plans to impose tariffs on most solar cells imported from Southeast Asia.</li>
<li>SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) jumped 13.6% to $13.74. SolarEdge Technologies will report financial results for the first quarter, before market open on Tuesday, May 6.</li>
<li>Webull Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BULL#NASDAQ">BULL</a>) shares rose 13.5% to $27.97.</li>
<li>Calix, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) jumped 13.1% to $37.59 after the company reported better-than-expected first-quarter financial results and issued second-quarter guidance above estimates. Additionally, the company announced an authorized increase to its stock repurchase program.</li>
<li>Bitdeer Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) jumped 12.2% to $8.52.</li>
<li>Riot Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) gained 11.1% to $6.99.</li>
<li>Equifax Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) gained 11% to $238.84 after the company reported better-than-expected first-quarter financial results. The company also authorized a $3 billion buyback and raised is dividend.</li>
<li>Seres Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) gained 10.5% to $8.27.</li>
<li>Akso Health Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) gained 8.8% to $1.22.</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) rose 8.8% to $213.04.</li>
<li>Pentair plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) climbed 7.3% to $84.70 after the company reported first-quarter financial results and beat its adjusted EPS and revenue estimates.</li>
<li>3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) shares gained 6.8% to $134.63 after the company reported better-than-expected first-quarter financial results.</li>
<li>Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) rose 5.8% to $195.64 after the company reported better-than-expected first-quarter EPS and revenue.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44922024/how-to-earn-500-a-month-from-philip-morris-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Philip Morris Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

BTDR

BULL

CALX

CIFR

CVNA

FSLR

HSAI

MCRB

RIOT

SEDG

Quest Diagnostics Posts Better-Than-Expected Earnings, Joins Pentair, 3M, Danaher And Other Big Stocks Moving Higher On Tuesday

Press Releases

Quest Diagnostics Reports First Quarter 2025 Financial Results; Reaffirms Revenue and Adjusted Diluted EPS Guidance for Full Year 2025

Oncologists Report Seeing More Advanced Cancers and Say Current Tests Are Not Catching Cancer Recurrence Early Enough, New Quest Diagnostics Report Finds

Dividends

Quest Diagnostics Declares Quarterly Cash Dividend

Quest Diagnostics to Speak at the William Blair 45th Annual Growth Stock Conference

More Americans Know Their Streaming Platform Passwords by Heart Than Their Cholesterol Score, New Survey Reveals

Contracts

Quest Diagnostics to Develop Multi-cancer Stratification (MCaST) Blood Test Based on MD Anderson Technology

Quest Diagnostics to Release Second Quarter 2025 Financial Results on July 22, 2025

Quest Diagnostics Releases 2024 Corporate Responsibility Report

Quest Diagnostics to Offer FDA-Cleared Fujirebio Blood Test for Alzheimer's Disease

Quest Diagnostics Introduces Testing for Oropouche Virus

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

Astrana Health

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Fresenius Medical Care

Guardant Health

Hims & Hers Health, Inc. Class A Common Stock

Hims & Hers Health

Hinge Health

LifeStance Health Group, Inc. - Common Stock

LifeStance Health Gr

Labcorp Hldgs

Pediatrix Medical Group, Inc. Common Stock

Pediatrix Medical Group

NeoGenomics

Omada Health

Option Care Health

OPKO Health

Premier

Privia Health Gr

RadNet

GeneDx Holdings Corp. - Class A Common Stock

Comments

Quest Diagnostics

Noticias

Últimas noticias sobre Quest Diagnostics (NYSE:DGX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL